Antimicrobial activities of mefloquine and a series of related compounds.

Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 05/2000; 44(4):848-52. DOI: 10.1128/AAC.44.4.848-852.2000
Source: PubMed

ABSTRACT Mefloquine was found to have bactericidal activity against methicillin- and fluoroquinolone-susceptible and -resistant strains of Staphylococcus aureus and Staphylococcus epidermidis and gentamicin- and vancomycin-resistant strains of Enterococcus faecalis and Enterococcus faecium. The MICs were 16 microg/ml, and the minimal bactericidal concentrations (MBCs) were 16 to 32 microg/ml. These concentrations cannot be achieved in serum. Mefloquine was active at a more achievable concentration against penicillin-susceptible and -resistant Streptococcus pneumoniae, with MICs of 0.2 to 1.5 microg/ml. Mefloquine was not active against gram-negative bacteria and yeasts. In an attempt to find more active derivatives, 400 mefloquine-related compounds were selected from the chemical inventory of The Walter Reed Army Institute of Research. We identified a series of compounds containing a piperidine methanol group attached to pyridine, quinoline, and benzylquinoline ring systems. These had activities similar to that of mefloquine against S. pneumoniae but were far more active against other gram-positive bacteria (MICs for staphylococci, 0.8 to 6.3 microg/ml). They had activities similar to that of amphotericin B against Candida spp. and Cryptococcus neoformans. Combinations of the compounds with gentamicin and vancomycin were additive against staphylococci and pneumococci. The MIC and MBC of gentamicin were decreased by four- to eightfold when this drug was combined with limiting dilutions of the compounds. There was no antagonism with other antimicrobial drugs. The compounds were rapidly bactericidal. They appear to act by disrupting cell membranes. Combinations of the compounds with aminoglycoside antibiotics may have potential for therapeutic use.


Available from: Calvin M Kunin, Apr 22, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malaria is a serious public health problem. More than 100 tropical and sub-tropical countries are endemic for malaria. Pregnant women and children are the most sensitive to this disease and more than 750 000 people die of malaria each year. Among the five species of Plasmodium, P. falciparum is the parasite responsible for the most serious form of the disease and it has developed varying degrees of resistance to many classes of antimalarial drugs; consequently the development of new drugs to treat malaria is in full rise. Mefloquine was proposed, for a long time, as the drug of choice for chloroquine-resistant malaria. Emergence of resistance to mefloquine and its associated severe side effects have limited the use of this drug. Nowadays, there is no effective alternative, especially, in the zone of multi-drug resistance. Since a few years, the mechanisms of resistance to antimalarial drugs, the mechanism of action of the mefloquine and the origin of the side effects begin to be understood. On these bases, several approaches are considered to enhance the design of the mefloquine including its synthesis as a pure enantiomer or even the modulation of the mefloquine core as a pure enantiomer.
  • [Show abstract] [Hide abstract]
    ABSTRACT: A mild and simple method was developed to prepare a series of fifteen 5-aminoimidazole 4-carboxamidrazones, starting from the easily accessible 5-amino-4-cyanoformimidoyl imidazoles. The antimicrobial activity of these novel amidrazones was screened against Gram positive (Staphylococcus aureus) and Gram negative (Escherichia coli, Pseudomonas aeruginosa) bacteria and Candida sp. (Candida albicans, Candida krusei, Candida parapsilosis). Only a subset of compounds displayed fair-moderate activity against S. aureus and E. coli but all exhibited activity against Candida sp. The three most potent antifungal compounds were further tested against Cryptococcus neoformans, Aspergillus fumigatus and three dermatophytes (Trichophyton rubrum, Trichophyton mentagrophytes, Microsporum gypseum). These three hit compounds strongly inhibited C. krusei and C. neoformans growth, although their activity on filamentous fungi was very weak when compared to the activity on yeasts.
    Bioorganic & Medicinal Chemistry Letters 10/2014; 24(19). DOI:10.1016/j.bmcl.2014.08.025 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: With the aim of developing a general and practical method for library production, a novel and efficient two-phase microwave-assisted cascade reaction between isatins and β-ketoamides in [Bmim]BF4/toluene was developed for the synthesis of pyrrolo[3,4-c]quinoline-1,3-diones. The features of this methodology are, the use of microwave-assisted rapid synthesis, mild reaction conditions, high yields, operational simplicity, facile product separation, and recyclability. Furthermore, the antibacterial activities of the pyrrolo[3,4-c]quinoline-1,3-dione derivatives produced were evaluated against Gram-negative bacteria (Escherichia coli, Pseudomonas aeruginosa, and Enterobacter aerogenes) and Gram-positive bacteria (Bacillus cereus and Staphylococcus aureus). These derivatives showed antibacterial activities against Gram-positive strains that were at least equivalent to that against Gram-negative strains. Compound 7{3,5} displayed the most potent antibacterial activity against P. aeruginosa (MIC: 0.5 µg/mL) and greater activity than standard ampicillin (MIC: 1 µg/mL). Compound 7{4,7} exhibited the best inhibitory activity against E. coli and E. aerogenes (MIC: 1 and 0.5 µg/mL), compared with the standard ampicillin (both MICs: 1 µg/mL). The synthesized pyrrolo[3,4-c]quinoline-1,3-diones are expected to be widely used as lead compounds for the development of new antibacterial agents.
    ACS Combinatorial Science 04/2014; 16(7):333. DOI:10.1021/co500002s · 3.40 Impact Factor